| scholarly article | Q13442814 |
| P50 | author | Sebastian Vogel | Q52654318 |
| P2093 | author name string | Swee Lay Thein | |
| P2860 | cites work | NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder | Q24317771 |
| Platelets in tissue repair: control of apoptosis and interactions with regenerative cells | Q26862152 | ||
| Emerging roles for platelets as immune and inflammatory cells | Q27016553 | ||
| Inflammasome in platelets: allying coagulation and inflammation in infectious and sterile diseases? | Q27692706 | ||
| HMG-1 as a late mediator of endotoxin lethality in mice | Q28139166 | ||
| High mobility group box 1 protein interacts with multiple Toll-like receptors | Q28280114 | ||
| P-Selectin–Mediated Platelet-Neutrophil Aggregate Formation Activates Neutrophils in Mouse and Human Sickle Cell Disease | Q30429416 | ||
| Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm | Q30476171 | ||
| Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli | Q30833776 | ||
| Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy. | Q33408183 | ||
| Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation | Q33410191 | ||
| Syndromes of thrombotic microangiopathy | Q33417044 | ||
| Sirtuin Inhibition Induces Apoptosis-like Changes in Platelets and Thrombocytopenia | Q33421625 | ||
| Activated platelets interfere with recruitment of mesenchymal stem cells to apoptotic cardiac cells via high mobility group box 1/Toll-like receptor 4-mediated down-regulation of hepatocyte growth factor receptor MET | Q33676193 | ||
| Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease | Q33749670 | ||
| Hemolysis-induced lethality involves inflammasome activation by heme | Q34314447 | ||
| The hypercoagulable state in thalassemia | Q34470268 | ||
| Sickle cell disease increases high mobility group box 1: a novel mechanism of inflammation. | Q34737543 | ||
| Auto-immune haemolytic anaemia--a high-risk disorder for thromboembolism? | Q35080336 | ||
| HMGB1 promotes the development of pulmonary arterial hypertension in rats | Q35208059 | ||
| HMGB1 promotes the activation of NLRP3 and caspase-8 inflammasomes via NF-κB pathway in acute glaucoma | Q35899312 | ||
| HMGB1 is a therapeutic target for sterile inflammation and infection | Q35953553 | ||
| Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin | Q35990633 | ||
| Necrotic cell-derived high mobility group box 1 attracts antigen-presenting cells but inhibits hepatocyte growth factor-mediated tropism of mesenchymal stem cells for apoptotic cell death. | Q36067773 | ||
| Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation | Q36186825 | ||
| Systemic inflammation and remote organ injury following trauma require HMGB1 | Q60692866 | ||
| Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis | Q61780011 | ||
| Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion | Q70656713 | ||
| Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity of The American Association for Thoracic Surgery and The Society of Thorac | Q71518235 | ||
| Platelet activation during steady state sickle cell disease | Q72792698 | ||
| Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia | Q73321111 | ||
| Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation | Q73387665 | ||
| Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease | Q74576929 | ||
| Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy | Q78208970 | ||
| Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation | Q81641908 | ||
| Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation | Q83118100 | ||
| Heme induces IL-1β secretion through activating NLRP3 in kidney inflammation | Q87166842 | ||
| Deacetylation-mediated interaction of SIRT1-HMGB1 improves survival in a mouse model of endotoxemia. | Q36237769 | ||
| Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects. | Q36335877 | ||
| Platelet-derived HMGB1 is a critical mediator of thrombosis. | Q36335907 | ||
| Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells | Q36407169 | ||
| Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology | Q36596850 | ||
| NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. | Q36839608 | ||
| Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. | Q36940035 | ||
| Hypercoagulability in sickle cell disease: new approaches to an old problem | Q37007280 | ||
| Platelets as cellular effectors of inflammation in vascular diseases | Q37081746 | ||
| Protective effects of sirtuin 3 in a murine model of sepsis-induced acute kidney injury | Q37251332 | ||
| Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease | Q37489028 | ||
| Platelets and the immune continuum | Q37857647 | ||
| Thrombosis and sickle cell disease. | Q37860232 | ||
| Expression of Toll-like receptors on human platelets | Q37866864 | ||
| Interplay between coagulation and vascular inflammation in sickle cell disease | Q38099667 | ||
| Sepsis and thrombosis | Q38102642 | ||
| Association of plasma CD40L with acute chest syndrome in sickle cell anemia | Q38727637 | ||
| Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase | Q38952745 | ||
| Sickle cell disease in the older adult | Q39028346 | ||
| Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1 | Q39645258 | ||
| Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein | Q40609759 | ||
| Erythroid DAMPs drive inflammation in SCD. | Q40650786 | ||
| Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells | Q40686939 | ||
| Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease | Q41065404 | ||
| Pathophysiologic implications of membrane phospholipid asymmetry in blood cells | Q41348596 | ||
| Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury | Q41457946 | ||
| Pathogenesis and treatment of sickle cell disease | Q41587302 | ||
| Platelet-derived high-mobility group box 1 promotes recruitment and suppresses apoptosis of monocytes | Q42155026 | ||
| Hypercoagulability and thrombotic complications in hemolytic anemias. | Q42604563 | ||
| Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities | Q42828870 | ||
| Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellular aggregates in sickle cell anemia | Q42979946 | ||
| Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion | Q43893061 | ||
| Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease | Q44404408 | ||
| Two new examples of Hb St. Etienne [beta 92(F8)HisGln] in association with venous thrombosis. | Q44638283 | ||
| Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy | Q44929555 | ||
| A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events | Q46178951 | ||
| Characterization of heme as activator of Toll-like receptor 4. | Q47787071 | ||
| The NLRP3 inflammasome and bruton's tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation. | Q51227901 | ||
| Platelet activation and inhibition in sickle cell disease (pains) study. | Q53117363 | ||
| Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia. | Q54104085 | ||
| Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis? | Q54596868 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 761-767 | |
| P577 | publication date | 2018-01-30 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Platelets at the crossroads of thrombosis, inflammation and haemolysis | |
| P478 | volume | 180 |
| Q90643177 | A Computational Approach for Mapping Heme Biology in the Context of Hemolytic Disorders |
| Q89896715 | Potential Therapeutic Anti-Inflammatory and Immunomodulatory Effects of Dihydroflavones, Flavones, and Flavonols |
| Q90314951 | TLR4-dependent upregulation of the platelet NLRP3 inflammasome promotes platelet aggregation in a murine model of hindlimb ischemia |
| Q96647332 | The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria |
| Q90290881 | The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth |
| Q57795879 | The platelet NLRP3 inflammasome is upregulated in sickle cell disease via HMGB1/TLR4 and Bruton tyrosine kinase |
| Q89967655 | Understanding Inflammatory Responses in the Manifestation of Prothrombotic Phenotypes |
Search more.